This study examined molecular predictors of ritlecitinib efficacy in treating alopecia areata, highlighting the role of JAK3-dependent inflammation and follicular integrity as important factors in understanding disease mechanisms and potential therapeutic effectiveness.
July 2024 in “Journal of Investigative Dermatology” OR101 may effectively treat atopic dermatitis and similar skin conditions.
40 citations
,
December 2016 in “Journal of Dermatological Treatment” This study reviewed the role of the JAK/STAT signaling pathway in skin diseases and the potential of JAK inhibitors for treating conditions like psoriasis and atopic dermatitis. Although the findings are promising, the authors concluded it is premature to establish their place in dermatological treatments.
9 citations
,
May 2023 in “Inflammation Research” This study reported that new drugs, despite lower specificity compared to certain immunobiological therapies, are effective across various challenging dermatological diseases, such as psoriasis, psoriatic arthritis, atopic dermatitis, alopecia areata, and vitiligo.
March 2018 in “Suez Canal University Medical Journal” This review examines targeting the JAK-STAT pathway in inflammatory skin diseases, highlighting existing JAK inhibitors and potential developments, but presents no new experimental or clinical results.